• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Kratom Update

A Kratom Update

January 1, 2017
Joshua Sonkiss, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Joshua Sonkiss, MD Editor-in-chief, The Carlat Addiction Treatment Report
If you have not yet heard of kratom (usually pronounced kray-tom or krah-tom), consider this an introduction to an herbal supplement that will likely be popping up in your newsfeeds with increasing frequency. Kratom (Mitragyna speciosa) is a tropical evergreen tree in the coffee family that has been used for centuries in Southeast Asia to boost energy and relieve pain. Kratom preparations are gaining popularity among substance users because of the plant’s opioid-like and stimulant properties. As with other opioids, regular use can cause physical dependence as well as withdrawal symptoms similar to opioid withdrawal.

Because of concerns about kratom’s addictive potential, the DEA had proposed classifying it as a Schedule I drug, in the same category as heroin. There was an outcry of protest, however, with many people advocating for its value as an opioid substitute both for pain ­treatment and to help opioid users curb their addictions. In a highly unusual move, the DEA postponed its decision, and as of now kratom is still legally sold (http://tinyurl.com/zttt6by). Since the DEA ban has been placed on the back burner, Florida and New York are considering bans at the state level.

Your patients are likely to obtain kratom either online or directly from “head shops.” It comes in a variety of forms, including leaves, powders, and capsules, with a typical dose costing in the range of $5–$10. On drug user forums such as Erowid, people report a subjective effect of initial stimulation, and later euphoria, with a duration of action around 2 to 4 hours. The main side effects appear to be sedation and nausea. At high doses, people report severe nausea, vomiting, and dizziness. Animal studies suggest there may be less ­respiratory depression with kratom than other opioids, but this has not been studied in humans. There have been deaths reported in users of kratom, though most were using it in conjunction with other substances. It’s worth noting that some prescribers have begun using buprenorphine to treat kratom use disorder. Although kratom won’t show up in routine drug tests, urine testing is available for mitragynine, one of kratom’s main psychoactive ­compounds.

Bottom line: Kratom is a plant with mild opioid-like properties that may well become addictive for some users. Overall, it appears to be less addictive than other opioids, whether prescription painkillers or street drugs. There’s a good chance, however, that it will soon become illegal, at least in some states.
Addiction Treatment
KEYWORDS addiction news_of_note substance-abuse
Joshua Sonkiss, MD

How to Read a Research Article

More from this author
www.thecarlatreport.com
Issue Date: January 1, 2017
SUBSCRIBE NOW
Table Of Contents
Take The CME Post-Test for Sex Addiction, CATR, January/February 2017
Cannabis and Psychosis: The Debate Continues
Sex Addiction: A Primer
Pornography Addiction
A Kratom Update
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.